



COMMONWEALTH OF
PUERTO RICO
P R E S S R E L E A S E

**COMMONWEALTH GOVERNOR ANNOUNCES IMPORTANT
INVESTMENT AND EXPANSION OF FORTUNE 500 PHARMACEUTICAL
COMPANY IN PUERTO RICO**

November 14, 2013 – San Juan – Today, on the World Diabetes Day, Governor Alejandro García Padilla, together with Lilly Pharmaceuticals executives, announced the expansion of the operations of this Fortune 500 company in Puerto Rico as part of the company’s strategy to satisfy the increased global demand for products for diabetics and position itself to produce potential new related products.

This expansion will inject approximately \$200 million during the next two years into the company’s insulin manufacturing plant in Carolina, Puerto Rico, and will create hundreds of direct and indirect construction related jobs.

“Through the expansion of this plant, Lilly will be able to satisfy, from Puerto Rico, the increased global demand for insulin and will be able to manufacture new products to treat diabetes,” the Governor stated, joined by Puerto Rico Industrial Development Company Executive Director Antonio Medina Comas, Department of Economic Development and Commerce Secretary Alberto Bacó, and Lilly’s President of Global Manufacturing Operations María Crowe.

This investment is the result of PRIDCO’s efforts to incorporate Puerto Rico in the expansion plans Lilly is implementing globally.

“Even though this is an investment aimed at strengthening its competitiveness and, therefore, does not imply a formal commitment to increase its labor force in this plant, Lilly anticipates that the construction works may create up to 400 temporary employment opportunities during two years, and up to 100 indirect jobs once the expansion of the plant is completed,” García Padilla explained.

On a separate note, Lilly's Executive María Crowe stated that "this investment will enhance our manufacturing capacity, provide employment opportunities, and require specialized services during the construction phase."

Lilly's announcement joins the announcements made by other multinational companies, such as, Covidien, Cooper Vision, Bristol Myers and General Electric, that have also demonstrated their confidence in Puerto Rico by expanding their operations on the Island. Seven out of the ten most sold medications in the world are manufactured in Puerto Rico, and twelve out of the twenty principal biopharmaceutical and biotechnology companies have operations in Puerto Rico.

Established in Puerto Rico since 1965, Lilly has approximately 1,600 employees on the Island. The company manufactures, in Puerto Rico, important pharmaceutical products, such as, Cymbalta®, Cialis®, Evista®, Strattera®, Symbyax®, Zyprexa®, and produces Humalog®, Forteo® and Humatrope® in bulk.

XXX

Contact: Jesús Manuel Ortiz – (787) 579 2231

Paola F. Figueroa Emanuelli – (787) 636 5352